PPM1D Is a Therapeutic Target in Childhood Neural Tumors
Authors:
- Jelena MilosevicJMJelena Milosevic
- Diana TreisDTDiana Treis
- Susanne FranssonSFSusanne Fransson
- Gabriel Gallo-OllerGGGabriel Gallo-Oller
- Baldur SveinbjörnssonBSBaldur Sveinbjörnsson
- Nina EisslerNENina Eissler
- Keiji TaninoKTKeiji Tanino
- Kazuyasu SakaguchiKSKazuyasu Sakaguchi
- Tommy MartinssonTMTommy Martinsson
- Malin WickströmMWMalin Wickström
- Per KognerPKPer Kogner
- John Inge JohnsenJJJohn Inge Johnsen
Open Access
Abstract
Childhood medulloblastoma and high-risk neuroblastoma frequently present with segmental gain of chromosome 17q corresponding to aggressive tumors and poor patient prognosis. Located within the 17q-gained chromosomal segments is PPM1D at chromosome 17q23.2. PPM1D encodes a serine/threonine phosphatase, WIP1, that is a negative regulator of p53 activity as well as key proteins involved in cell cycle control, DNA repair and apoptosis. Here, we show that the level of PPM1D expression correlates with chromosome 17q gain in medulloblastoma and neuroblastoma cells, and both medulloblastoma and neuroblastoma cells are highly dependent on PPM1D expression for survival. Comparison of different inhibitors of WIP1 showed that SL-176 was the most potent compound inhibiting medulloblastoma and neuroblastoma growth and had similar or more potent effects on cell survival than the MDM2 inhibitor Nutlin-3 or the p53 activator RITA. SL-176 monotherapy significantly suppressed the growth of established medulloblastoma and neuroblastoma xenografts in nude mice. These results suggest that the development of clinically applicable compounds inhibiting the activity of WIP1 is of importance since PPM1D activating mutations, genetic gain or amplifications and/or overexpression of WIP1 are frequently detected in several different cancers.Keywords
This publication has 85 references indexed in Scilit:
- Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpointJournal of Cell Biology, 2013
- WIP1 Enhances Tumor Formation in a Sonic Hedgehog–Dependent Model of MedulloblastomaNeurosurgery, 2012
- Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumorsBMC Genomics, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Oncogenic Wip1 Phosphatase Is Inhibited by miR-16 in the DNA Damage Signaling PathwayCancer Research, 2010
- High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed NeuroblastomaClinical Cancer Research, 2010
- High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onsetProceedings of the National Academy of Sciences, 2010
- Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1DJournal of Neuro-Oncology, 2007
- Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphataseJournal of Experimental Medicine, 2006
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004